Clinical trials: Histological Response
Metastatic Melanoma, Recurrent Cutaneous Melanoma
Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma
This phase II trial studies how well ibrutinib works in treating patients with stage IV melanoma of the skin that has not responded to previous treatment.
- Conditions
- Metastatic Melanoma, Recurrent Cutaneous Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7
- Trial name
- NCT02581930
- Testing
- Ibrutinib, Laboratory Biomarker Analysis, Pharmacogenomic Study
- Where
- 13 sites in United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia
Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients
To investigate the feasibility of delivering oral azacitidine (CC-486) as a consolidation regimen from the time of first complete remission (CR1), in patients with acute myelogenous leukemia (AML) eligible for curative intent…
- Trial name
- NCT06180863
- Testing
- oral azacitidine (CC-486)
- Where
- United States
- Sponsor
- Yale University
Squamous Cell Carcinoma
QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with SCC who have progressed on or after previous platinum-based chemotherapy and anti-PD-1/PD-L1 therapy.
- Trial name
- NCT03387111
- Testing
- Aldoxorubicin HCl, ETBX-011, ETBX-021
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- ImmunityBio, Inc.
Bone Sarcoma, Osteosarcoma
Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas
Randomized, non-comparative, multicentre exploratory phase II study. Two arms concerning patients with bone sarcoma after the first line therapy: in the first arm, patients will be treated with Regorafenib for a maximum of 12…
- Conditions
- Bone Sarcoma, Osteosarcoma, Ewing Sarcoma, Chondrosarcoma
- Trial name
- REGOSTA (NCT04055220)
- Testing
- Treatment by Regorafenib, Surveillance
- Where
- 16 sites in France
- Volunteers
- 168 people
- Sponsor
- Centre Leon Berard
Melanoma, Brain Metastases
Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases
The purpose of this research project is to test the effectiveness of nivolumab versus nivolumab together with ipilimumab for the treatment of melanoma brain metastases.
- Trial name
- ABC (NCT02374242)
- Testing
- Nivolumab, Ipilimumab
- Where
- 4 sites in Australia
- Volunteers
- 76 people
- Sponsor
- Melanoma Institute Australia
Leukemia
Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to…
- Trial name
- NCT00016159
- Testing
- filgrastim, lintuzumab, arsenic trioxide
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hodgkin Disease
Study of Ofatumumab and ESHAP for the Treatment of Hodgkin's Lymphoma
The aim of this study is to analyze the efficacy of O-ESHAP treatment for Hodgkin's lymphome patients that have a first line chemotherapy treatment failure due to refractoriness, partial response or relapsed.
- Trial name
- NCT01195766
- Testing
- Ofatumumab
- Where
- 14 sites in Spain
- Volunteers
- 64 people
- Sponsor
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Malignant Melanoma
Study of a DNA Immunotherapy to Treat Melanoma
The study is an investigation of a novel immunotherapy, SCIB1, for the treatment of melanoma. SCIB1 is a solution of plasmid DNA molecules which will express a modified antibody in human cells.
- Trial name
- NCT01138410
- Testing
- SCIB1
- Where
- 5 sites in United Kingdom
- Volunteers
- 35 people
- Sponsor
- Scancell Ltd
Leukemia, Chronic Myeloid
Malaysia Stop Tyrosine Kinase Inhibitor Trial
To compare administration of peginterferon-α-2a for 1 year versus observation after stopping tyrosine kinase inhibitor (TKI) in chronic myeloid leukemia (CML) patients with deep MR ≥ 2 years.
- Trial name
- MSIT (NCT02381379)
- Testing
- Peginterferon-α-2a
- Where
- 9 sites in Malaysia
- Volunteers
- 118 people
- Sponsor
- Ministry of Health, Malaysia
Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
The purpose of the study is to evaluate the safety and tolerability of pepinemab in combination with pembrolizumab as first-line treatment and determine a recommended Phase 2 dose (RP2D) in patients with recurrent or metastatic…
- Trial name
- KEYNOTE-B84 (NCT04815720)
- Testing
- pepinemab + pembrolizumab
- Where
- 15 sites in United States
- Volunteers
- 49 people
- Sponsor
- Vaccinex Inc.
Epithelial Neoplasms, Malignant, Epithelial Tumors, Malignant
NHS-IL12 for Solid Tumors
Background: The experimental drug NHS-IL12 may help the immune system become more active and kill cancer cells that have not responded to standard treatments.
- Conditions
- Epithelial Neoplasms, Malignant, Epithelial Tumors, Malignant, Malignant Mesenchymal Tumor
- Trial name
- NCT01417546
- Testing
- NHS-IL-12
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute (NCI)
Philadelphia Positive (Ph+) Chronic Myeloid Leukemia
Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to Nilotinib
Primary Objective for this study is to evaluate changes in chronic low grade non-hematological adverse events experienced by patients who have been treated with at least 6 months of imatinib and who have not responded to…
- Trial name
- MACS1532 (NCT02115386)
- Testing
- Nilotinib
- Where
- Russia
- Volunteers
- 7 people
- Sponsor
- Novartis Pharmaceuticals
Squamous Cell Carcinoma of the Head and Neck
Expansion Trial for Axitinib In Head And Neck Cancer
This study will be a prospective, single-institution, single-arm phase II study of Axitinib in patients with unresectable recurrent and metastatic head and neck squamous cell carcinoma.
- Trial name
- NCT02762513
- Testing
- Axitinib
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Michigan Rogel Cancer Center
Hepatoblastoma
A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy
A Phase 3 multi-institutional study for treatment of children with newly diagnosed hepatoblastoma using a modified Paediatric Hepatic International Tumour Trial (PHITT) strategy incorporating a randomized assessment of sodium…
- Trial name
- NCT04478292
- Testing
- Sodium Thiosulfate Injection, Primary surgery resection, mono CDDP-Group A2
- Where
- China
- Volunteers
- 330 people
- Sponsor
- Shanghai Children's Medical Center
Chronic Myelocytic Leukemia
Assess Long-term Feasibility of Reduced Dose Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients
This study is conducted in patients with newly diagnosed CP CML (Chronic Phase Chronic Myeloid Leukemia) who have achieved EMR (< 10% IS BCR-ABL) at 3 months after first line treatment with dasatinib.
- Trial name
- NCT04150471
- Testing
- RQ-PCR(Real-time Quantitative Polymerase chain reaction) RNA Analysis
- Where
- South Korea
- Volunteers
- 79 people
- Sponsor
- Seoul St. Mary's Hospital
Follicular Lymphoma
Signatures of Response and Resistance to Mosunetuzomab in Follicular Lymphomas (FL)
Mosunetuzumab is a T-cell bispecific antibody targeting CD20 and CD3 aiming to redirect T cells to engage and eliminate malignant B cells.
- Trial name
- NCT05529524
- Where
- 9 sites in France
- Volunteers
- 6 people
- Sponsor
- The Lymphoma Academic Research Organisation
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL
This phase II trial studies the side effects of nivolumab and to see how well it works when given together with ifosfamide, carboplatin, and etoposide in treating patients with Hodgkin lymphoma that has come back (relapsed) and…
- Trial name
- NCT03016871
- Testing
- Carboplatin, Etoposide, Ifosfamide
- Where
- 4 sites in United States
- Volunteers
- 78 people
- Sponsor
- City of Hope Medical Center
Glioblastoma
VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma
VXM01 phase I pilot study in patients with operable recurrence of a glioblastoma to examine safety, tolerability, immune and biomarker response to the investigational VEGFR-2 DNA vaccine VXM01
- Trial name
- NCT02718443
- Testing
- VXM01
- Where
- Germany
- Volunteers
- 14 people
- Sponsor
- Vaximm GmbH
Melanoma, Neoplasm Metastasis
Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
This experiment will test the safety and effectiveness of a treatment for melanoma in which certain lymphocytes (a type of white blood cell) are taken from the patient, grown in the laboratory, and returned after the patient's…
- Trial name
- NCT00001832
- Testing
- gp100:209-217 (210M), Montanide ISA-51, IL-2
- Where
- United States
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
COVID-19, SARS-CoV-2 Infection
Clinical Characteristics and Outcomes of Pediatric COVID-19
Rationale: The clinical manifestations of SARS-CoV-2 infection in children are poorly characterized. Preliminary findings indicate that they may be atypical.
- Conditions
- COVID-19, SARS-CoV-2 Infection, Pediatric ALL, Pneumonia, Viral
- Trial name
- PERN-COVID-19 (NCT04330261)
- Testing
- Exposure (not intervention) - SARS-CoV-2 infection
- Where
- Canada
- Volunteers
- 10,610 people
- Sponsor
- University of Calgary
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.